Haris Ali, MD, City of Hope

Articles

Overview of the ROCKstar Study

September 12th 2024

Medical experts discuss the data that led to belumosudil’s FDA approval.

Overview of Advanced Therapies in cGVHD

September 12th 2024

Medical experts discuss advanced therapies in cGVHD.

Navigating Treatment Decisions in Chronic GVHD

September 5th 2024

Medical experts discuss criteria for switching GVHD treatments and how to choose between available treatment options.

Optimizing Chronic GVHD Therapy

September 5th 2024

Medical experts discuss overall goals for cGVHD treatment as well as concerns with long-term corticosteroid use in treatment.

Navigating Chronic GVHD: Phases of Pathophysiology and Best Practices in Patient Monitoring

August 29th 2024

Medical experts discuss navigating chronic GVHD.

Differentiating Acute and Chronic Graft-vs-Host Disease

August 29th 2024

After a brief introduction, Shernan Holtan, MD, and Haris Ali, MD, discuss the distinction between acute and chronic graft-vs-host disease.

Dr. Ali on Key Findings From the Phase 1 Study of Selinexor Plus Ruxolitinib in Myelofibrosis

October 11th 2022

Haris Ali, MD, discusses a phase 1 dose-escalation trial investigating the administration of selinexor in combination with ruxolitinib for patients with treatment-naïve myelofibrosis.

Dr. Ali on Ruxolitinib and Navitoclax Combination Therapy in Myelofibrosis

September 30th 2022

Haris Ali, MD, discusses the investigation of ruxolitinib and navitoclax combination therapy in myelofibrosis.

HSCT Approaches to Retain GVL While Preventing GVHD

May 6th 2022

Expert perspectives on novel transplantation strategies to prevent or improve outcomes in graft-versus-host disease.

Novel Targeted Agents in GVHD: The FLIGHT and AGAVE-201 Trials

May 6th 2022

Brief insight on the FLIGHT and AGAVE-201 trials in chronic GVHD, which analyzed itacitinib, a JAK inhibitor, and axatilimab, a CSF1R inhibitor, respectively.

Chronic GVHD: Novel Treatment Approaches With Approved Agents

April 29th 2022

Considerations for novel treatment approaches with approved agents in combination or the frontline setting of chronic graft-vs-host disease.

Selecting Second-Line Therapy for Chronic GVHD

April 29th 2022

Shared insight on how best to select ibrutinib, belumosudil, or ruxolitinib for patients with steroid-refractory chronic graft-vs-host disease.

Chronic GVHD: Real-World Use of Ruxolitinib

April 22nd 2022

Closing out his summation of ruxolitinib in chronic GVHD, Yi-Bin Chen, MD, considers how real-world use compares with the REACH3 trial results.

REACH3 Trial: Approval of Ruxolitinib in Chronic GVHD

April 22nd 2022

Comprehensive insight on the design and results of REACH3, which analyzed ruxolitinib as second-line therapy for chronic graft-vs-host disease.

Mechanism of Action of Ruxolitinib

April 15th 2022

In the context of chronic graft-vs-host disease, expert Yi-Bin Chen, MD, provides an overview of ruxolitinib’s mechanism of action.

Belumosudil’s Approval and Use in Chronic Graft-Vs-Host Disease

April 15th 2022

Haris Ali, MD, shares insight on belumosudil, a ROCK2 inhibitor approved in the management of chronic graft-vs-host disease.

Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease

April 8th 2022

Corey Cutler, MD, MPH, FRCPC, breaks down the mechanism of action and FDA approval of ibrutinib, a BTK inhibitor, in chronic graft-versus-host disease.

Identifying and Managing Steroid-Refractory Chronic GVHD

April 8th 2022

Expert perspectives on optimal treatment strategies for patients who develop steroid-refractory chronic graft-versus-host disease.

Defining Steroid-Refractory and Steroid-Dependent GVHD

April 1st 2022

Yi-Bin Chen, MD outlines the definition of steroid-refractory vs steroid-dependent graft-vs-host disease.

Frontline Treatment Options for Chronic GVHD

April 1st 2022

A comprehensive breakdown of frontline treatment strategies for patients with newly diagnosed chronic graft-vs-host disease.